Table 2.
Characteristics of patients (pt) who survived at least 10 years (yr) following diagnosis of Her2+ metastatic breast cancer (MBC) (N=12).
| Pt | Age at initial diagnosis | Stage at initial diagnosis | HR status | Time to MBC (yr) | CNS mets | Initial metastatic sitê | Biopsy proven mets | Time to 2nd-line therapy (years) | OS* | Duration of anti-Her2 therapy for MBC (yr) | Anti-Her2 therapy | NED at last follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61 | 36 | II | + | 3.6 | Yes | Multiple | Yes | 1.7 | >10.1 | continues | T, L, A, P | No |
| 97 | 48 | II | − | 2.9 | No | Visceral | Yes | NA | >10.1 | 9.9 | T | Yes |
| 47 | 40 | III | + | 2.5 | No | Multiple | Yes | 1.3 | 10.3 | 1.2 | T, L | No |
| 76 | 46 | II | + | 2.0 | Yes | Bone | No | 5.4 | 10.4 | intermittent | T, L | No |
| 220 | 41 | I | + | 2.3 | No | Multiple | Yes | 0.2 | >11.6 | continues | T, A, P | No |
| 83 | 34 | I | + | 5.2 | No | Multiple | No | 2.9 | >11.6 | continues | T | No |
| 187 | 55 | II | − | 2.2 | No | Bone | Yes | NA | >12.5 | 0.4 | T | Yes |
| 96 | 50 | 1 | + | 3.0 | No | Visceral | Yes | NA | >12.7 | continues | T | Yes |
| 176 | 42 | II | − | 1.9 | Yes | Multiple | Yes | 1.7 | >14.1 | >9.3 | T | Yes |
| 59 | 66 | IV | + | At diagnosis | No | Visceral | Yes | NA | >14.2 | 2.5 | T | Yes |
| 41 | 37 | II | + | 1.5 | No | Visceral | Yes | NA | >15.2 | 12.0 | T | Yes |
| 93 | 26 | IV | + | At diagnosis | No | Bone | No | 1.4 | >16.3 | continues | T | Yes |
Abbreviations: A: ado-trastuzumab emtansine; CNS: central nervous system; HR: hormone receptor; L: lapatinib; met: metastasis; NA: no progression to date; NED: no evidence of disease; OS: overall survival; P: pertuzumab; T: trastuzumab.
*
Survival for patients still alive at time of data cutoff is censored.